INC Research

syneoshealth.com

INC Research/inVentiv Health has become Syneos Health, the only fully integrated end-to-end clinical and commercial solution organization. We are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. Our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

news image

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

news image

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More

Industry Outlook

REGENERX LICENSEE ACQUIRED BY KOREAN BIOPHARMACEUTICAL GROUP

RegeneRx Biopharmaceuticals, Inc. | September 28, 2021

news image

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S. GtreeBNT announced that as part of its acquisition the company would issue approximately US$80 million of new stock and convertible bonds to HLB Grou...

Read More

Industrial Impact, Medical

ELEMENTAL MACHINES PARTNERS WITH SYSTEM-C BIOPROCESS TO BRING ITS IOT HARDWARE SOLUTIONS TO THE EUROPEAN BIOPHARMACEUTICAL INDUSTRY

Prnewswire | March 30, 2023

news image

Elemental Machines, developer of the Intelligent Operations Platform, has entered into a partnership with System-c bioprocess as an authorized reseller of Elemental Machines' hardware solutions, servicing the biopharmaceutical industry in France. The partnership will allow Elemental Machines to expand its footprint further in European markets. System-c serves as a partner and distributor for benchmark brands that cover a range of bioprocessing products from screening to filt...

Read More
news image

Industrial Impact

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More
news image

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More
news image

Industry Outlook

REGENERX LICENSEE ACQUIRED BY KOREAN BIOPHARMACEUTICAL GROUP

RegeneRx Biopharmaceuticals, Inc. | September 28, 2021

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S. GtreeBNT announced that as part of its acquisition the company would issue approximately US$80 million of new stock and convertible bonds to HLB Grou...

Read More
news image

Industrial Impact, Medical

ELEMENTAL MACHINES PARTNERS WITH SYSTEM-C BIOPROCESS TO BRING ITS IOT HARDWARE SOLUTIONS TO THE EUROPEAN BIOPHARMACEUTICAL INDUSTRY

Prnewswire | March 30, 2023

Elemental Machines, developer of the Intelligent Operations Platform, has entered into a partnership with System-c bioprocess as an authorized reseller of Elemental Machines' hardware solutions, servicing the biopharmaceutical industry in France. The partnership will allow Elemental Machines to expand its footprint further in European markets. System-c serves as a partner and distributor for benchmark brands that cover a range of bioprocessing products from screening to filt...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us